Jacobs Levy Equity Management’s Denali Therapeutics DNLI Stock Holding History

Jacobs Levy Equity Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-45,969	Closed	-$667K	–	959
2025 Q3	$667K	Buy	+45,969	New	+$661K	﹤0.01%	778
2021 Q3	–	Sell	-7,679	Closed	-$602K	–	1057
2021 Q2	$602K	Sell	7,679 -37,617	-83%	-$2.33M	﹤0.01%	831
2021 Q1	$2.59M	Buy	+45,296	New	+$3.03M	0.02%	544
2019 Q3	–	Sell	-11,660	Closed	-$242K	–	941
2019 Q2	$242K	Buy	+11,660	New	+$261K	﹤0.01%	847

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management's DNLI Position: Q4 2025 in Review

Jacobs Levy Equity Management sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 45,969 shares — an estimated $667K sold.

Jacobs Levy Equity Management first reported a position in DNLI in Q2 2019 and held it in 4 quarters. The position peaked at $2.59M in Q1 2021. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Jacobs Levy Equity Management reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 45,969 Denali Therapeutics shares in Q4 2025, an estimated $667K.
Jacobs Levy Equity Management first reported a position in Denali Therapeutics in Q2 2019 and held it in 4 quarters.
Jacobs Levy Equity Management's Denali Therapeutics position peaked at $2.59M in Q1 2021.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.